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Abstract
Purpose To investigate fixed-dosing aflibercept for treating
polypoidal choroidal vasculopathy (PCV).
Methods This phase IV, prospective, single-arm, interven-
tional case series was conducted in eight centers. Forty
treatment-naïve PCV patients were administered three
monthly doses of intravitreal aflibercept (2.0 mg) and an
injection every 2 months thereafter. Best-corrected visual
acuity (BCVA) and central subfield macular thickness
(CSMT) were measured at each visit. Fluorescein and in-
docyanine green angiography (ICGA) were performed at
baseline, 3 and 12 months. The primary outcome measure
was the proportion of patients who maintained BCVA (<15
letters loss) at 12 months. Changes in BCVA, macular ap-
pearance, and polypoidal lesion appearance were also
examined.
Results Thirty-five eyes (87.5 %) had maintained BCVA at
12 months. Average BCVA was significantly higher at
12 months (20/53, 64.2 letters) than at baseline (20/80, 55.1
letters, 9-letter gain; P < .001). Mean CSMTwas significantly
lower at 12 months (253.6 μm) than at baseline (365.2 μm,
P < .001). The macula was dry in 32 (76.2 %), 27 (64.3 %),
and 24 eyes (60.0 %) at 3, 6, and 12 months respectively.
Fourteen eyes (33.3 %) had a fluid recurrence or increase at
6 months, and they had a significantly lower vision gain
(P = .005) than other patients at 12 months. Complete polyp
regression occurred in 26 eyes (66.7 %) at 12 months.
Conclusions Fixed-dosing aflibercept showed favorable out-
comes in PCV patients at 12 months. However, some patients
had worse outcomes because of fluid recurrence during main-
tenance dosing, and these patients would require additional
treatments.
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Introduction
Polypoidal choroidal vasculopathy (PCV) is a subtype of ex-
udative age-related macular degeneration (AMD) that can
cause permanent vision loss due to hemorrhage, exudation,
macular edema, and disciform scar formation. This type of
AMD has been reported to account for approximately 10 %
of exudative AMD cases in Western populations [1] and ap-
proximately 50 % of exudative AMD cases in Asian popula-
tions [2]. Ranibizumab is now the first-line therapy for treating
PCV, in replacement of photodynamic therapy (PDT), be-
cause it significantly improves vision after monthly intravitre-
al injections of the agent [3, 4].
Interestingly, PCV responds differently than typical AMD
to intravitreal anti-vascular endothelial growth factor (VEGF)
treatments. Persistent subretinal fluid [5] and polypoidal ves-
sels [6, 7] are common despite bevacizumab or ranibizumab
treatment. However, PDT with verteporfin was superior to
ranibizumab monotherapy over the short term in terms of
anatomical parameters [8]. Nevertheless, anti-VEGF treat-
ment seems more promising than PDT. Visual acuity was
not maintained with PDT treatment over the long term [9,
10] and eyes treated with ranibizumab had better functional
outcomes than eyes treated with PDT after 1 year [11, 12].
Additionally, the VEGF Trap-Eye Investigation of Efficacy
and Safety inWet AMD (VIEW) 1 and 2 studies demonstrated
that aflibercept is equally effective for treating wet AMD as
ranibizumab, but it has a longer treatment interval [13].
Several studies have also shown that treatment of PCV with
aflibercept results in good functional results and, frequently,
polyp closure [14–17].
However, prior studies were limited by a short follow-up
period [14, 15], a single-center setting [16], or a retrospective
design [17]. Although the VIEW studies included PCV pa-
tients, the diagnosis was not confirmed with indocyanine
green angiography (ICGA). The purpose of the current study
was to prospectively evaluate the effect of intravitreal injec-
tion of VEGF-Trap Eye on polypoidal choroidal vasculopathy
in treatment-naïve patients (VAULT).
Methods
Study design
The VAULT study was designed as a phase IV, prospective,
multicenter, interventional, single-arm, single-dose clinical tri-
al (ClinicalTrials.gov ID NCT01950741). Patients diagnosed
with PCV were recruited between September 2013 and
July 2014 at eight hospitals across South Korea. The
protocol was approved by the Institutional Review
Board/Ethics Committee at each participating hospital. All
study conduct adhered to the tenets of the Declaration of
Helsinki, and all subjects provided written informed consent
to participate in this study.
Inclusion and exclusion criteria
A scanning laser ophthalmoscope (HRA-2; Heidelberg
Engineering, Heidelberg, Germany) was used to perform fluo-
rescein angiography (FA) and indocyanine green angiography
(ICGA). A PCV diagnosis was given if ICGA showed
polypoidal vessel dilation with or without a branching vascu-
lar network (BVN). Subjects were considered for participation
if all of the following were true: diagnosed with the PCV
subtype of exudative AMD via ICGA, polypoidal lesion lo-
cated within 3,000 μm of the foveal center, and best-corrected
visual acuity (BCVA) between 20/40 and 20/320. Subjects
also had to have fluorescein dye leakage (as shown on FA)
and/or evidence of intraretinal, subretinal, or sub-retinal pig-
ment epithelium (RPE) fluid (as shown on optical coherence
tomography [OCT]).
Subjects were excluded if any of the following were true:
1) presence of a subretinal hemorrhage or other pathology that
blocked at least 50% of the PCV lesion in ICGA, 2) history of
intravitreal anti-VEGF or photodynamic therapy, 3) history of
intraocular surgery (except uncomplicated cataract surgery
performed more than 3 months before enrollment), 4) other
ocular disease known to affect vision (e.g., glaucoma, visually
significant cataract), 5) uncontrolled systemic disease (e.g.,
diabetes, high blood pressure, cardiovascular disease, cerebro-
vascular disease), 6) active infection inside or around the eye,
or 7) hypersensitive reaction to aflibercept or other injection
components.
Treatment and assessment schedule
Intravitreal injection of aflibercept (2.0mg in 0.05ml) through
the pars plana was performed under aseptic conditions. Three
monthly doses were followed by a maintenance injection ev-
ery 2 months for a total of a 12-month treatment period (total
of seven injections). At each visit, BCVA (ETDRS chart) and
intraocular pressure were measured. Slit-lamp biomicroscopy,
color fundus photography, and spectral-domain OCT were
performed before injections. Using OCT images, central sub-
field macular thickness was measured as the average thickness
of the central 1 mm thickness map measurement area. Both
FA and ICGA were obtained at baseline, 3 and 12 months.
Photodynamic therapy with verteporfin was used as a rescue
treatment, and was performed at the treating physician’s dis-
cretion at 6 months or later.
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Outcome measures
The primary outcome measure was the proportion of patients
who maintained BCVA, defined as losing <15 ETDRS letters
over the 12-month study period. Secondary outcome mea-
sures included the following: mean change in BCVA from
baseline at 12 months, proportion of patients with a BCVA
of 20/200 or better at 12 months, proportion of patients with a
BCVA of 20/40 or better at 12 months, proportion of patients
who had complete intraretinal/subretinal fluid resolution at
12 months, proportion of patients who had complete
polypoidal lesion disappearance at 12months based on ICGA.
All study images were collected from each participating
center, and were interpreted by three of the authors (JEL,
JEL, and HWK). When disagreements occurred, images were
discussed until a consensus was reached. Polyp changes were
categorized at 3 and 12 months as complete regression, partial
regression, persistent, or newly developed. Enlargement of
BVNs was also assessed. Macular drying was categorized as
complete, incomplete, or persistent, and fluid levels were
compared with those at the previous visit. The BVN area
and polypoidal lesion size were measured in ICGA images
at baseline using ImageJ software (National Institutes of
Health, ver. 1.49). The size of the largest polypoidal lesion
was defined as the largest linear dimension of the largest
polypoidal dilation in ICGA images. Location of the PCV
lesion and the polypoidal lesion closest to the foveal center
was categorized as subfoveal, juxtafoveal, and extrafoveal.
Statistical analyses
Non-parametric tests (Wilcoxon signed-rank and Mann–
Whitney U tests) were used to compare measured values,
and Spearman’s ranked correlation was used to examine cor-
relations between measurements. Categorical variables were
analyzed using Fisher’s exact test or Chi-square test.
Statistical significance was defined as P < .05. SPSS statistical
software (ver. 17.0 for Windows, IBM Corp., Armonk, NY,
USA) was used to perform statistical analyses.
Results
A total of 48 patients were enrolled in the study, but 40 pa-
tients (27 male, 13 female) were ultimately included in anal-
yses (Table 1). Three patients dropped out of the study before
the end of the 12-month follow-up period, and five patients
were excluded because ICGA did not show definitive PCV.
The mean age of included subjects was 67.0 ± 9.2 years
(range: 44–84 years). Location of vascular lesion was
subfoveal in 19 eyes. Mean BVN area was 3.39 ± 4.10 mm2
(range: 0.32–24.81 mm2). Number of polypoidal lesions were
3.6 in average (range 1–28), and mean largest polyp size was
286.0 ± 115.7 μm (range: 131–666 μm). The polyp closest to
the foveal center was subfoveal in one eye, juxtafoveral in 12
eyes and extrafoveal in 27 eyes. One eye underwent one ses-
sion of PDT at 8 months (during maintenance dosing) to treat
a marked increase in subretinal fluid and severe vision loss.
Visual acuity
Mean BCVA improved from 20/80 (55.1 ± 18.2 letters) at
baseline to 20/53 (64.2 ± 16.1 letters) at 12 months (9.0 ±
18.1 letter gain, P < .001). Significant improvements were ob-
served as early as 1 month after the first injection (Fig. 1a). A
total of 35 (87.5 %) of 40 eyes did not lose more than 15 letters
of vision at 12 months. At this time point, 13 eyes (32.5 %)
had an improvement in BCVA of 15 letters or more, 22 eyes
(55.0 %) had change of <15 letters, and five eyes (12.5 %) lost
15 or more letters (Fig. 2a).
The number of eyes with a visual acuity of 20/40 or better
increased from seven eyes (17.5 %) at baseline to 21 eyes
(52.5 %) at 12 months (P = .001). Additionally, the number
of eyes with a visual acuity worse than 20/200 changed from
six eyes (15.0 %) at baseline to two eyes (5.0 %) at 12 months
(P = .263; Fig. 2b). Better baseline visual acuity was associat-
ed with less visual gain (r = −.561, P < .001) and better BCVA
(r = .461, P = .003) at 12 months. Juxtafoveal location of pol-
yp was the baseline factor related to more visual gain
(P = .044). There was no association between the final
BCVA and the other baseline factors; polyp size (P = .437),
Table 1 Baseline characteristics of patients with polypoidal choroidal
vasculopathy who were treated with intravitreal aflibercept on a fixed-
dosing schedule
N (eyes) 40




Mean (ETDRS letters) 55.1 ± 18.2
Median (Snellen) 20/60
Central subfield macular thickness (μm) 365.2 ± 104.6
Location of vascular lesion (eyes)
Subfoveal 19 (47.5 %)
Juxtafoveal 5 (12.5 %)
Extrafoveal 16 (40.0 %)
Area of branching vascular network (mm2) 3.39 ± 4.10
Number of polypoidal lesions 3.6 (1–28)
Size of the largest polypoidal lesion (μm) 286.0 ± 115.7
Location of the polyp closest to the foveal center (eyes)
Subfoveal 1 (2.5 %)
Juxtafoveal 12 (30.0 %)
Extrafoveal 27 (67.5 %)
ETDRS Early Treatment of Diabetic Retinopathy Study
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polyp number (P = .339), location of polyp (P = .766), loca-
tion of lesion (P = .482), or BVN area (P = .885).
Anatomical outcomes
Mean central subfield macular thickness, as measured by
OCT, significantly decreased from 365.2 ± 104.6 μm at base-
line to 226.8 ± 50.9 μm at 3 months (P < 0.001) and to 253.6
± 99.7 μm at 12 months (P < .001; Fig. 1b). Qualitative as-
sessments on intraretinal/subretinal/subRPE fluid was per-
formed in 42 eyes, including two eyes that dropped out of
the study after 6 months (Fig. 3a). All eyes had a reduction
in fluid after the initial loading dose of intravitreal aflibercept
(three monthly injections). The macula was completely dry in
32 (76.2 %), 27 (64.3 %), and 24 eyes (60.0 %) at 3, 6, and
12 months respectively.
After switching to the bimonthly injection maintenance
schedule, fluid reappeared or increased in 14 (33.3 %) eyes
at 6 months (Figs. 3a and 4). The group of eyes had a signif-
icantly worse final outcome at 12 months than the group of
eyes that did not have fluid recurrence. The recurrent group
had a lower rate of complete dryness (23.1 % vs 77.8 %,
P < .001), a worse BCVA (55.5 ± 13.9 letters vs 68.3 ± 15.5
letters, P = .018, Fig. 5), and a lower vision gain (−1.5 ± 12.4
vs +14.1 ± 18.5 letters, P = .005). Baseline characteristics of
these two groups were not significantly different (Table 2).
Additionally, six (22.2 %) of 27 eyes that had a dry macula
at 6 months had fluid recurrence at 12 months.
A polypoidal lesion was identified on ICGA at baseline in
all eyes. After the initial aflibercept loading dose (three
monthly injections), complete polyp regression was observed
in 26 eyes (61.9 %), partial regression was observed in ten
eyes (23.8 %), no change was observed in four eyes (9.5 %),
and a new polypoidal lesion was observed in two eyes (4.8 %)
(Fig. 3b). Average size of the largest polypoidal lesion at base-
line was not different between eyes with and without complete
polyp regression at either 3 (P = .847) or 12 (P = .965)
months. At 12 months, 26 eyes (66.7 %) had complete polyp
regression, and nine eyes (23.1 %) had developed a new pol-
yp. The BVN area increased in three eyes (7.1 %) during the
loading period (2.65 to 3.32 mm2), and in 14 eyes (35.9 %)
thereafter (2.53 to 5.27 mm2), which included four eyes that
remained completely dry during the maintenance period
(Fig. 6).
Adverse events
Adverse events were assessed in all of the enrolled patients.
Serious adverse events were reported in one patient (2.1 %),
who died of pneumonia. The 73-year-old man had
Fig. 1 a Mean change in best-corrected visual acuity and b central
subfield macular thickness in eyes with polypoidal choroidal
vasculopathy treated with aflibercept on a fixed dosing schedule (three
initial monthly injections followed by bimonthly maintenance injections).
* indicates a statistically significant difference from baseline (P < .05).
Error bars indicate quartile values
Fig. 2 a Proportion of patients
with improved, maintained, or
decreased visual acuity. b
Distribution of visual acuity.
M =months
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experienced mild cerebral ischemia 4months before the event,
and administration of aflibercept had been discontinued.
Conjunctival hemorrhage related with the injection procedure
was the most common adverse event noted. Increase of
subretinal hemorrhage was noted in three eyes (6.3 %). An
RPE tear also occurred in two eyes (4.2 %). Other adverse
events included urticaria of the skin (one subject), tinnitus
(one subject), and headache (one subject).
Discussion
Our prospective study of a fixed-dose aflibercept regimen for
treating eyes with treatment-naïve PCV had favorable visual
outcomes, with BCVA maintained or improved in 87.5 % (35
of 40 eyes). On average, BCVA improved by 9 letters over
12 months, and approximately half of all patients had a BCVA
of 20/40 or better. However, there was a group of patients that
responded poorly to maintenance dosing schedule (injection
every 2 months).
The first line of treatment for PCV is somewhat debatable,
unlike for typical AMD. Several studies have compared the
efficacies of ranibizumab and PDT, but have reported conflict-
ing results in anatomical and functional outcomes. The
EVEREST study [8] was a prospective, multi-center clinical
trial that compared the efficacy of PDT combined with intra-
vitreal ranibizumab, verteporfin PDT monotherapy, and intra-
vitreal ranibizumab monotherapy for treating eyes with PCV.
Complete regression of polypoidal lesions occurred more fre-
quently in eyes receiving PDT, and there was no difference in
visual acuity between the combination and ranibizumab
monotherapy groups. Kokame et al. [6] reported polyp regres-
sion in 33 % of eyes 6 months after beginning monthly
ranibizumab injections. Based on these results, Koh et al.
[18] suggested that verteporfin PDT, with or without
ranibizumab, should be the first-line treatment in eyes with
PCV to induce polyp regression.
However, verteporfin PDT monotherapy has been shown
to result in smaller visual gains than intravitreal ranibizumab
monotherapy, even though PDT results in a more effective
reduction in central macular thickness and a more frequent
regression of polyps [8, 11, 12]. Performing PDT resolved
intra- and/or subretinal fluid in eyes with PCV that did not
respond to anti-VEGF treatments, but visual acuity was not
maintained [19]. Potential side-effects of PDT, including dam-
age to photoreceptors and the RPE, were thought to be the
cause of this anatomical and functional outcome discrepancy.
Therefore, it was suggested that polyp regression and exuda-
tive improvements do not necessarily translate into a good
visual outcome [12]. Nevertheless, anatomical outcomes are
important for securing long-term results because persistent
subretinal fluid and/or a sudden, massive submacular hemor-
rhage can result in permanent visual impairment.
In the present study, a standard aflibercept loading dose
(three monthly injections) was initially administered and was
followed by injections administered every 2 months. This
treatment schedule was the same as that used in the VIEW
studies [13]. Complete regression of polypoidal lesions oc-
curred in 61.9 % of patients at 3 months and in 66.7 % of
patients at 12 months. This regression rate was comparable to
that obtained with PDT and other studies examining
aflibercept therapy (55.4–75.0 % polyp closure rate)
[14–17]. It hasd been shown that aflibercept has a stronger
affinity for VEGF-A than ranibizumab, and also that it blocks
VEGF-B and PlGF [20, 21]. These drug biological character-
istics would explain the higher polyp closure rate with
aflibercept than with ranibizumab.
The VIEW 1 and VIEW 2 trials [13] demonstrated a mean
gain of 7.9 and 8.9 letters respectively in patients with wet
AMD. Another study also showed a 0.14 logMAR unit
Fig. 3 Flowcharts of a retinal fluid changes assessed with optical coherence tomography, and b polyp regression assessed with indocyanine green
angiography during the study period. * indicates that one eye underwent rescue photodynamic therapy
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(equivalent to 7 ETDRS letters) gain in visual acuity in eyes
with PCV treated with aflibercept [17]. In these studies and
ours, visual acuity was maintained between 3 and 12 months
while subjects received injections every 2 months.
Nonetheless, in the current study, the proportion of eyes that
lost <15 letters changed from 98 % at 3 months to 88 % at
Fig. 4 Fundus photographs (left column), optical coherence tomography
images (center column), and indocyanine green angiography (ICGA,
right column) images of a 60-year-old man with polypoidal choroidal
vasculopathy (PCV) treated with a fixed-dosing regimen of aflibercept
(three initial monthly injections followed by bimonthly injections). a–c
At baseline, subretinal fluid (SRF) and a pigment epithelial detachment
(PED) related to PCVare apparent. Visual acuity was 20/40. A branching
vascular network and polypoidal vessels are visible on ICGA. d–f At
3 months, SRF had resolved even though polypoidal lesions had only
partially regressed. g, h New SRF is visible 6 (arrow). I, j A subretinal
hemorrhage and a large PED are noted. k–mAlthough SRF had resolved,
visual acuity had decreased to 20/125 and new polypoidal lesions devel-
oped, as visible on ICGA (arrows)
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Table 2 Characteristics of
patients with polypoidal choroidal
vasculopathy who had a
maintained or recurred sub/
intraretinal fluid after extending
the aflibercept treatment interval
from 1 month to 2 months
Maintained Recurred P value
N (eyes) 27 (67.5 %) 13 (32.5 %)
Sex (male/female) 18/9 9/4 >.999a
Age (years) 67.7 ± 9.6 65.6 ± 8.4 .508b
Laterality (right/left) 9/18 6/7 .498a




Area of branching vascular network (mm2) 3.86 ± 4.88 2.41 ± 1.24 .732b
Number of polyps 3.3 (1–11) 3.0 (1–28) .632b
Size of the largest polypoidal lesion (μm) 288.5 ± 101.4 280.7 ± 145.5 .441b




Central subfield macular thickness (μm) 368.4 ± 104.6 358.5 ± 108.7 .842b
Completely dry (eyes)
Month 3 19 (70.4 %) 8 (61.5 %) .721 a
Month 6 26 (96.3 %) 0 (0 %) <.001a
Month 12 21 (77.8 %) 3 (23.1 %)c <.001a
Visual acuity (letters)
Baseline 54.3 ± 20.0 56.9 ± 14.2 .670b
Month 3 66.1 ± 15.1 60.0 ± 15.2 .276b
Month 6 69.5 ± 16.1 57.1 ± 15.1 .019b
Month 12 68.3 ± 15.5 55.5 ± 13.9 .018b
Visual acuity gain (letters)
Month 3 11.9 ± 14.5 3.1 ± 7.3 .039b
Month 6 15.3 ± 15.5 0.2 ± 14.9 .005b
Month 12 14.1 ± 18.5 −1.5 ± 12.4 .005b
a indicates P value calculated with a Fisher’s exact test
b indicates P value calculated with a Mann–Whitney U test
c includes one eye that underwent rescue photodynamic therapy
Fig. 5 Mean visual acuity in eyes
with polypoidal choroidal
vasculopathy treated with
aflibercept every 2 months
following three monthly loading
injections. An increase in
subretinal/intraretinal fluid was
noted in 14 eyes after extending
the treatment interval from 1 to
2 months. Patients with recurrent
fluid had a significantly worse
visual acuity than patients with no
recurrence. * indicates a
statistically significant difference
between groups (P < .05). Error
bars indicate quartile values
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12 months. This may have occurred because of retinal fluid
recurrence in approximately one-third of eyes after the treat-
ment interval was extended to 2 months (Fig. 4). These find-
ings are probably related to the ‘saw teeth’ phenomenon in
central macular thickness that has been observed previous
studies [13, 17]. However, some of our patients developed a
subretinal hemorrhage (Fig. 5) or a substantial increase in
subretinal fluid and required rescue PDT. Not surprisingly,
eyes with increased fluid at 6 months also had a worse final
visual acuity. Therefore, the conventional bimonthly mainte-
nance dosing schedule is suboptimal for some patients, and
more intensive treatments (e.g., more frequent injections and/
or PDT) may be needed. Unfortunately, no associations be-
tween fluid recurrence and baseline characteristics were
found, and we cannot predict which patients will need more
intensive treatments. However, vision gain after loading injec-
tions and fluid status 6 months into treatment may be predic-
tors of long-term outcomes.
New polyp formation and branching BVN enlargement
were observed on ICGA during continued injections at fixed
2 month intervals. Another study reported similar findings,
showing that the proportion of patients with a smaller lesion
size than at baseline decreased from 25.6 % at 3 months to
13.4 % at 12 months [17]. It is worth mentioning that 4 eyes
Fig. 6 Fundus photographs (left column), indocyanine green
angiography images (ICGA, middle column), and optical coherence
tomography (OCT) images (right column) obtained from a 63-year-old
man with polypoidal choroidal vasculopathy (PCV) treated with fixed-
dosing aflibercept. a, bAt baseline, exudative changes related to PCVare
apparent with branching vascular network (BVN) and polypoidal vessels
noted on ICGA images (arrows). c, dAlthough polyps present at baseline
completely regressed after three monthly injections, BVN growth and
new polyp formation occurred at 3 months (arrows). e, f New polyps
and BVN growth were still present at 12 months (arrows on ICGA
image). g–l Study OCT images shown that the macula remained dry from
3 to 12 months
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included in the current study had a BVN size increase even
though the macula remained dry throughout the maintenance-
dosing period. It may be that threshold anti-VEGF agent
levels needed to prevent PCV growth are different than those
needed to suppress exudative changes. It may also be that
mechanisms not related to VEGF are involved in BVN
growth. The relationship between PCV lesion growth and
long-term outcomes should be studied in eyes without exuda-
tive changes to better understand these other mechanisms.
There was one serious adverse event of death, of which
cause was pneumonia. Although it did not appear to be related
to intravitreal aflibercept that had been discontinued 5 months
before.
Our study had several limitations. We did not have a com-
parison control group. The examined number of cases was
relatively small and the follow-up period was relatively short.
However, the fact that this was a prospective study on a ho-
mogeneous group of PCV patients that included data from
different sites makes our data robust.
In conclusion, 12 month anatomical and functional out-
comes were favorable after administering aflibercept on a
fixed dosing schedule (3 monthly injections followed by bi-
monthly injections) to treat treatment-naïve PCV. However,
fluid recurrence was observed in one-third of patients after
extending the treatment interval to 2 months. Because final
outcomes in these patients were poor, a more flexible treat-
ment strategy should be used. Larger studies with a longer
follow-up period that compare treatment strategies (e.g., pro-
re-nata or treat-and-extend dosing) are warranted.
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